Search

Your search keyword '"Peyvandi F"' showing total 1,725 results

Search Constraints

Start Over You searched for: Author "Peyvandi F" Remove constraint Author: "Peyvandi F"
1,725 results on '"Peyvandi F"'

Search Results

1. L’Association du caplacizumab aux echanges plasmatiques et au traitement immunosuppresseur améliore le pronostic du PTT autoimmun acquis : une étude internationale de vraie vie (Projet Capla 500+)

4. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

6. Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy

7. Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

8. Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

9. Correction to: Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register (Internal and Emergency Medicine, (2023), 18, 4, (1049-1063), 10.1007/s11739-023-03254-3)

10. Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register

13. Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes

20. PB0313 Towards the Standardisation of ADAMTS-13 Antibody Testing in Thrombotic Thrombocytopenic Purpura (TTP)-Results of the IMATAS Collaborative Study

22. PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry

25. OC 50.3 Inhibitor Development Upon Switch After 50 EDs from Plasma-Derived to Recombinant FVIII in Pups with Severe Haemophilia A: The PUP-SWITCH Study Results

27. LB 01.1 Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age with Severe Hemophilia A

29. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1

31. PB0683 Patients at Higher Risk of Spontaneous Joint Bleeding during Emicizumab Prophylaxis: A Study on Global Coagulation Assays and Arthropathy Scores

33. OC 69.5 Outcomes in Adult and Adolescent Patients with Severe Hemophilia a in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis from an Observational Study with Factor VIII Prophylaxis

35. PB0316 Bortezomib for the Treatment of Multi-Refractory Immune-Mediated Thrombotic Thrombocytopenic Purpura: An Italian Multicenter Survey

36. OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy

43. OC 42.3 Immune-Mediated TTP Patients in Remission with Recovered ADAMTS13 Activity but an Open ADAMTS13 Conformation are at Risk for Earlier ADAMTS13 Relapse

46. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement

48. Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis

49. Minimal factor XIII activity level to prevent major spontaneous bleeds

Catalog

Books, media, physical & digital resources